Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain caused by neuroinflammation, a condition that may develop as a result of a wide number of underlying diseases and lead to severely reduced cognition and alertness.
The results from an internationally acclaimed clinical Phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling, cognition and alertness in patients with the liver disease hepatic encephalopathy.
The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but its mechanism of action is also relevant in a number of other indication areas, including neurodegenerative diseases such as Parkinson’s disease.